Karyopharm Therapeutics Inc. (KPTI) — 10-Q Filings

10-Q Filings (6)

• Karyopharm's Net Loss Widens Amid Liquidity Concerns — Nov 3, 2025 Risk: high
  Karyopharm Therapeutics Inc. reported a net loss of $33.1 million for the three months ended September 30, 2025, a slight increase from $32.1 million in the sam
• Karyopharm Q2 Revenue Dips, Net Loss Narrows Amid Cost Cuts — Aug 11, 2025 Risk: medium
  Karyopharm Therapeutics Inc. reported total revenue of $34.7 million for the three months ended June 30, 2025, a decrease from $38.9 million in the prior-year p
• Karyopharm Therapeutics Files Q1 2025 10-Q — May 12, 2025 Risk: medium
  Karyopharm Therapeutics Inc. filed its 10-Q for the period ending March 31, 2025. The company reported on its financial position, including details on its commo
• Karyopharm Therapeutics Files Q3 2024 10-Q — Nov 5, 2024 Risk: medium
  Karyopharm Therapeutics Inc. filed its 10-Q for the period ending September 30, 2024. The company reported on its financial performance, including details on it
• Karyopharm Therapeutics Files Q2 2024 10-Q — Aug 6, 2024 Risk: medium
  Karyopharm Therapeutics Inc. filed its 10-Q for the period ending June 30, 2024. The company reported financial results and provided updates on its business ope
• Karyopharm Therapeutics Inc. Files 10-Q for Period Ending March 31, 2024 — May 8, 2024 Risk:
  Karyopharm Therapeutics Inc. (KPTI) filed a Quarterly Report (10-Q) with the SEC on May 8, 2024. Karyopharm Therapeutics Inc. filed a 10-Q report for the quarte

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX